No Data
8-K: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Reports Q3 EPS (25c), Consensus (25c)
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024
Reviva Pharm Holdings 3Q Loss/Shr 25c >RVPH
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital
Reviva Pharm Holdings Price Target Maintained With a $15.00/Share by D. Boral Capital
Stock_Drift OP T-24Century : What’s that ?